This AOP is licensed under a Creative Commons Attribution 4.0 International License.
5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring
Point of Contact
- Terje Svingen
|Author status||OECD status||OECD project||SAAOP status|
|Under development: Not open for comment. Do not cite||Under Development||1.90||Included in OECD Work Plan|
This AOP was last modified on June 04, 2021 16:31
|5α-reductase, inhibition||April 18, 2019 19:48|
|Decrease, dihydrotestosterone (DHT) level||April 10, 2019 05:22|
|Decrease, androgen receptors (AR) activation||April 10, 2019 05:24|
|decrease, male anogenital distance||June 09, 2020 12:07|
|Altered, Transcription of genes by AR||November 04, 2020 11:11|
|5α-reductase, inhibition leads to Decrease, DHT level||April 18, 2019 19:54|
|Decrease, DHT level leads to Decrease, AR activation||February 02, 2021 05:50|
|Finasteride||November 29, 2016 18:42|
This AOP links 5α-reductase inhibition during fetal life with short anogenital distance (AGD) in male offspring. A short AGD around birth is a marker for feminization of male fetuses and is associated with male reproductive disorders, including reduced fertility in adulthood. Although a short AGD is not necessarily ‘adverse’ from a human health perspective, it is considered an ‘adverse outcome’ in OECD test guidelines; AGD measurements are mandatory in specific tests for developmental and reproductive toxicity in chemical risk assessment (TG 443, TG 421/422, TG 414).
5α-reductase is an enzyme responsible for the conversion of testosterone to DHT in target tissues. DHT is more potent agonist of the Androgen receptor (AR) than testosterone, so that DHT is necessary for proper masculinization of e.g. male external genitalia. Under normal physiological conditions, testosterone produced mainly by the testicles, is converted in peripheral tissues by 5α-reductase into DHT, which in turn binds AR and activates downstream target genes. AR signaling is necessary for masculinization of the developing fetus, including differentiation of the levator ani/bulbocavernosus (LABC) muscle complex in males. The LABC complex does not develop in the absence, or low levels of, androgen signaling, as in female fetuses.
The key events in this pathway is inhibition of 5α-reductase that converts testosterone into the more potent DHT in androgen sensitive target tissues. This includes developing perineal region, which, when DHT levels are low or absent, leads to inactivation of the AR and failure to properly masculinize the perineum/LABC complex.
AOP Development Strategy
Summary of the AOP
Molecular Initiating Events (MIE)
Key Events (KE)
Adverse Outcomes (AO)
|Type||Event ID||Title||Short name|
|MIE||1617||5α-reductase, inhibition||5α-reductase, inhibition|
|KE||1613||Decrease, dihydrotestosterone (DHT) level||Decrease, DHT level|
|KE||1614||Decrease, androgen receptors (AR) activation||Decrease, AR activation|
|KE||286||Altered, Transcription of genes by AR||Altered, Transcription of genes by AR|
|AO||1688||decrease, male anogenital distance||short male AGD|
Relationships Between Two Key Events (Including MIEs and AOs)
|5α-reductase, inhibition leads to Decrease, DHT level||adjacent||High||High|
|Decrease, DHT level leads to Decrease, AR activation||adjacent|
Life Stage Applicability
Overall Assessment of the AOP
Domain of Applicability
Essentiality of the Key Events
Known Modulating Factors
Considerations for Potential Applications of the AOP (optional)
- Schwartz CL, Christiansen S, Vinggaard AM, Axelstad M, Hass U and Svingen T (2019), Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders. Arch Toxicol 93: 253-272.